Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 136 AL 150

An update on drug treatment options of Alzheimer's disease

Allgaier M, Allgaier C.

Front Biosci (Landmark Ed). 2014 Jun 1;19(8):1345-54. doi: 10.2741/4285.

Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?

Macdonald IR, Rockwood K, Martin E, Darvesh S.

J Alzheimers Dis. 2014;42(2):379-84. doi: 10.3233/JAD-140219.

Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014

Froestl W, Muhs A, Pfeifer A.

J Alzheimers Dis. 2014;41(4):961-1019. doi: 10.3233/JAD-140228.

[Antipsychotic use in the cohort PACA-Alz in patients with Alzheimer's disease and other dementia in 2010]

Bonin-Guillaume S, Martin G, Zafack J, Gentile G, Allaria-Lapierre V, Sciortino V, Thirion X, Micallef J.

Therapie. 2014 May-Jun;69(3):213-22. doi: 10.2515/therapie/2014015. Epub 2014 Jun 6.

Ryanodine receptors: physiological function and deregulation in Alzheimer disease

Del Prete D, Checler F, Chami M.

Mol Neurodegener. 2014 Jun 5;9:21. doi: 10.1186/1750-1326-9-21.

Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014

Froestl W, Muhs A, Pfeifer A.

J Alzheimers Dis. 2014;42(1):1-68. doi: 10.3233/JAD-140402.

Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study

Freund-Levi Y, Vedin I, Hjorth E, Basun H, Faxén Irving G, Schultzberg M, Eriksdotter M, Palmblad J, Vessby B, Wahlund LO, Cederholm T, Basu S.

J Alzheimers Dis. 2014;42(3):823-31. doi: 10.3233/JAD-132042.

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial

Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, Frydman-Marom A, Zisapel N.

Clin Interv Aging. 2014 Jun 18;9:947-61. doi: 10.2147/CIA.S65625. eCollection 2014.

Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease

Poirier J, Miron J, Picard C, Gormley P, Théroux L, Breitner J, Dea D.

Neurobiol Aging. 2014 Sep;35 Suppl 2(Suppl 2):S3-10. doi: 10.1016/j.neurobiolaging.2014.03.037. Epub 2014 May 15.

Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease

Wang P, Ding K.

Protein Pept Lett. 2014;21(10):1048-56. doi: 10.2174/0929866521666140626095145.

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?

Panza F, Solfrizzi V, Imbimbo BP, Logroscino G.

Expert Opin Biol Ther. 2014 Oct;14(10):1465-76. doi: 10.1517/14712598.2014.935332. Epub 2014 Jun 30.

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings

Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC.

Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14.

Epigenetic drug discovery for Alzheimer's disease

Cacabelos R, Torrellas C.

Expert Opin Drug Discov. 2014 Sep;9(9):1059-86. doi: 10.1517/17460441.2014.930124. Epub 2014 Jul 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias